TITLE

Pipeline

PUB. DATE
August 2007
SOURCE
Medical Marketing & Media;Aug2007, Vol. 42 Issue 8, p10
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) submitted by Barr Laboratories Inc. to market the generic version of Dostinex. Ferring Pharmaceuticals announces the receipt of the approval from the FDA for Endometrin to treat infertile women. Shire receives an approval letter from the FDA for Intuniv release extension for treating children with hyperactivity disorder.
ACCESSION #
26025570

 

Related Articles

  • COMPANY SPOTLIGHT - Shire Pharmaceuticals.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p17 

    This article presents information related to the business and research activities of Shire Pharmaceuticals Inc. The U.S. FDA has approved Shire's Adderall XR to be used in the treatment of attention deficit hyperactivity disorder in adolescents aged 13 to 17. The FDA based its approval on data...

  • Renovo Licenses Juvista To Shire In $825M Deal.  // Bioworld Week;6/25/2007, Vol. 15 Issue 26, p5 

    The article reports on the partnership of Renovo Group PLC and Shire PLC for dealing with the anti-scarring drug Juvista in 2007. Shire has won out by offering a package that includes $125 million up front, which is $75 million in cash and $50 million in equity purchased at $3.97 per share....

  • CNS News Round-Up.  // PharmaWatch: CNS;Sep2005, Vol. 4 Issue 9, p2 

    This article presents news briefs related to the pharmaceutical industry. It has definitely been a good four weeks for Shire Pharmaceuticals Inc. as the FDA has given an approval for its attention deficit hyperactivity disorder treatment Adderall XR and the company believes its MTS patch...

  • FDA Takes Slow Road Toward Withdrawal of Drug Approved With Fast-Track Process. Mitka, Mike // JAMA: Journal of the American Medical Association;3/9/2011, Vol. 305 Issue 10, p982 

    The article focuses on the move of the U.S. Food and Drug Administration (FDA) to slow its withdrawal procedure for midodrine hydrochloride from Shire Pharmaceuticals, which was approved in 1996 for the treatment of symptomatic orthostatic hypotension. According to the FDA, it expects the drug...

  • Shire Pharmaceuticals: promising pipeline.  // PharmaWatch: Monthly Review;Mar2007, Vol. 6 Issue 3, p24 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the ulcerative colitis drug Lialda from Shire Pharmaceuticals Group PLC. The FDA approval of Lialda is positive news for pharmaceutical companies: Shire, Giuliani and Cosmo Pharmaceuticals SpA. Its minimum once a...

  • ADHD drug given Schedule II classification.  // Drug Topics;5/21/2007, Vol. 151 Issue 10, 0 p10 

    The article reports that attention-deficit hyperactivity disease (ADHD) prodrug lisdexamfetamine dimesylate with a brand name Vyvanse from Shire Pharmaceuticals Group PLC will be considered a Schedule II substance, according to the U.S. Drug Enforcement Association. The consideration of the...

  • CNS News Round-Up.  // PharmaWatch: CNS;Nov2008, Vol. 7 Issue 11, p2 

    The article offers news briefs related to the pharmaceutical industry in the U.S. GlaxoSmithKline, Pharmacopeia and the Center of Excellence for External Drug Discovery have discovered a drug compound for treating inflammatory pain. Barr Laboratories Inc. has obtained approval from the Food and...

  • Delay of Plan B switch decision draws charge of political pandering.  // Drug Store News;2/14/2005, Vol. 27 Issue 2, p19 

    Reports on the controversy over the decision of the Food and Drug Administration to delay judgment on Barr Laboratories Inc.'s application to switch its emergency contraceptive Plan B from Rx to OTC. Injunction to mandate a Plan B switch; Factors influencing the decision of the agency; Criticism...

  • Shire Withdraws US Bid For Fabry Drug.  // MondayMorning;3/19/2012, Vol. 20 Issue 12, p1 

    The article presents information on Shire Pharmaceuticals Group Plc. which has withdrawn its bid for the drug Replagal Biologic, which is used to treat a genetic disorder called Fabry disease, for the U.S. Food and Drug Administration (FDA) approval. Shire has issued a statement according to...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics